A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Age
18–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent
BMI ≥30 kg/m2 or BMI ≥27.0 kg/m2 and previous/current diagnosis of ≥ 1 obesity related comorbidity
You may not be if
Previous documented diagnosis of diabetes mellitus.
Self-reported change in body weight \>5% within 3 months before Screening
Body weight ≤80 kg at Screening
Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening)
Clareo Health | A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
